Although a minority of asthma patients suffer from severe asthma, they represent a major
clinical challenge in terms of poor symptom control despite high-dose treatment, risk of …

Background: Few studies have provided real-world evidence of mepolizumab efficacy and
safety. We aimed to evaluate mepolizumab for severe eosinophilic asthma in daily clinical …

Randomised controlled trials (RCTs) are universally considered as the gold standard for
evaluating the efficacy of treatments. Their main strength is that, through randomisation, they …

Background Severe asthma is a high impact disease. Omalizumab targets the allergic
inflammatory pathway; however, effectiveness data in a population with significant …

Background The severe forms of asthma represent a major burden, because of severity of
symptoms, costs and impact on everyday life. Recently, Mepolizumab (MEP) was approved …

Overlapping eligibility to different biologics for severe asthma is still challenging, especially
when addressing the same target. We aimed to characterize severe eosinophilic asthma …

Even if severe asthma (SA) accounts for 5–10% of all cases of the disease, it is currently a
crucial unmet need, owing its difficult clinical management and its high social costs. For this …

Background Asthma is an inflammatory disease of the airways with symptoms that vary over
time and intensity, sometimes leading to disability or even death. Eosinophilic asthma …

Background This retrospective study aimed at evaluating long-term effects of Omalizumab in
elderly asthmatics in a real-life setting. Methods 105 consecutive severe asthmatics (GINA …

Background In patients with asthma, particularly severe asthma, poor adherence to inhaled
drugs negatively affects the achievement of disease control. A better adherence rate is …